Table 2.

Factors associated with survival outcomes

Characteristic		Progression-free survival						Overall survival
		Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
		HR	95% CI	p-value	aHR	95% CI	p-value	HR	95% CI	p-value	aHR	95% CI	p-value
Age (yr)
	< 55	1			1			1			1
	≥ 55	1.590	1.273-1.985	< 0.001	1.325	1.043-1.683	0.021	2.237	1.218-4.107	0.009	1.704	0.904-3.211	0.099
FIGO stage
	I-II	1			1			1			1
	III	2.435	1.746-3.397	< 0.001	2.296	1.563-3.371	< 0.001	1.502	0.613-3.678	0.374	1.078	0.378-3.079	0.888
	IV	3.568	2.478-5.139	< 0.001	2.637	1.681-4.138	< 0.001	2.768	1.068-7.176	0.036	1.490	0.465-4.775	0.502
Histology
	High-grade serous	1			1			1			1
	Non–high-grade serous	0.620	0.472-0.813	0.001	1.085	0.795-1.483	0.607	0.803	0.396-1.625	0.541	1.219	0.545-2.724	0.630
Primary treatment strategy
	PDS	1			1			1			1
	NAC	2.103	1.657-2.670	< 0.001	1.511	1.131-2.019	0.005	2.071	1.117-3.837	0.021	2.003	0.969-4.142	0.061
Residual tumor after PDS/IDS
	< 1 cm	1			1			1			1
	≥ 1 cm	1.738	1.229-2.457	0.002	1.310	0.894-1.918	0.166	2.729	1.381-5.395	0.004	2.676	1.261-5.678	0.010
BRCA mutational status
	Wild-type	1			1			1			1
	Mutation	0.914	0.718-1.164	0.467	0.765	0.593-0.987	0.040	1.156	0.627-2.131	0.642	1.163	0.623-2.171	0.636

HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; FIGO, International Federation of Gynecology and Obstetrics; PDS, primary debulking surgery; NAC, neoadjuvant chemotherapy; IDS, interval debulking surgery.